Ion Exchange India Ltd

AGM details and access

• 62nd AGM scheduled for Sep 11, 2026 at 11:00 IST via VC/OVAM.
• Electronic AGM notice and FY2025-26 annual report sent only to registered email holders.
• Record date for dividend set at Aug 31, 2026.
• e-voting window: Sep 7–10, 2026; cut-off Sep 4, 2026.
• Dividend payable within 30 days after the AGM.

Email addresses and notices process

• Shareholders without registered emails will receive access via web link.
• Demat holders: update email with Depository Participant; physical holders: update with RTA.

RTA contact

• RTA: MUFG Intime India Private Limited handles shareholder updates.

Key highlights

• Revenue from operations: INR 267,890.54 Lakh; +5.5% YoY.
• EBITDA: INR 27,928.38 Lakh.
• PAT: INR 13,837.92 Lakh.
• PAT margin: 5.17%.
• Diluted EPS: INR 11.257.
• Dividend proposed: INR 1.25 per share; record date 31-Aug-2026.
• Net debt: INR 21,067.50 Lakh.
• Capex: PPE additions INR 38,916.56 Lakh.
• Aquanomics revenue: INR 13,656.31 Lacs.
• Lease liabilities total: INR 2,778.30 Lacs.

Overview

• Standalone BRSR for FY2025-26; Ion Exchange India Ltd.
• Main activities across three segments: Engineering, Chemical, Consumer.
• Turnover mix: Engineering 60%, Chemical 25%, Consumer 15%.
• Assurance from TÜV SÜD; Limited assurance.

Key ESG Risks & Opportunities

• Water & Waste Management: Opportunity; efficiency gains at scale.
• Safe Chemistry & Process Innovation: Opportunity; premium markets through green products.
• Quality of Products & Project Delivery: Opportunity; strengthens revenue and customer trust.
• Climate Change & Energy Management: Risk; mitigate via energy efficiency and renewables.
• Responsible Sourcing: Risk; supplier codes and audits reduce reputational/regulatory risk.
• Occupational Health & Safety: Risk; robust OHSMS and hazard controls reduce incidents.

Governance & Policy Highlights

• Board oversight with a dedicated sustainability group led by MD & CEO.
• Anti-bribery, whistleblower, and human rights policies; policy web links provided.
• Limited assurance on BRSR by TÜV SÜD South Asia.
• Board-level SRC oversees shareholder grievances; quarterly reporting.

Social Responsibility & Workforce

• Total employees 3,108; 2,975 permanent; 248 female; 7.98% female share.
• Board and KMP female representation: 1 of 10 (10%); 1 of 4 (25%).
• LTIFR zero; no fatalities in FY2025-26.
• CSR via Ion Foundation: 50+ projects; 60,955 beneficiaries; 100% from vulnerable groups.
• Accessibility: disability-friendly offices in multiple cities; equal opportunity policy in place.
• Return-to-work rate after parental leave: 100% for permanent staff.

Environmental Performance

• Total energy: 131,802.95 GJ; renewables 1,772.44 GJ; non-renewables 130,030.51 GJ.
• GHG emissions: Scope 1 4,375 tCO2e; Scope 2 12,888 tCO2e.
• Energy intensity: 0.000000644 tCO2e per INR; PPP-adjusted 0.00001298 tCO2e per USD.
• Water withdrawal 397,152 KL; consumption 174,665 KL; intensity 0.00000652 KL/INR.
• Waste: total 14,303 MT; hazardous waste 14,047 MT; plastic 0.060 MT; batteries 0.908 MT.
• GHG reduction: rooftop solar 1,606 kWp; ZLD pilots; ISO 14001/45001; carbon targets.

Stakeholder Engagement & Complaints

• Stakeholders include investors, shareholders, customers, suppliers, employees, communities; SRC oversees grievances.
• Shareholders filed 9 complaints in FY2025-26; 0 pending; all resolved.
• Communities complaints: 0; continuous engagements across local partners and CSR activities.
• Gujarat wastewater PPP project informed by stakeholder input.

Other Notable Metrics

• Sustainable sourcing: 67% inputs from suppliers with sustainability practices; 28.53% from MSMEs; 93.22% Indian inputs.
• Data privacy/cybersecurity: policies linked; data breaches: nil.
• Product recalls: Nil; cyber incidents: Nil; no material adverse product safety events.
• CSR: over 50 projects; 60,955 beneficiaries; 100% from vulnerable groups.

AGM Details

• AGM scheduled for Friday, 11 September 2026 at 11:00 AM IST via VC/OAVM.
• Venue deemed at Registered Office; meeting conducted through VC/OAVM as per MCA/SEBI guidelines.
• Cut-off date for remote e-voting: 4 September 2026.

Resolutions proposed

• Ordinary: Adopt standalone and consolidated financial statements and reports.
• Ordinary: Dividend on equity shares to be declared.
• Ordinary: Re-appointment of Dinesh Sharma, retiring by rotation.
• Special: Ratify cost auditors' remuneration for FY2027 at INR 4,75,000 plus taxes.

Voting results

• Voting results are not disclosed in this notice.

Director changes

• Dinesh Sharma to be re-appointed; retiring by rotation as Non-Executive Non-Independent Vice-Chairman.

Financial Performance

• Consolidated operating income ₹701 crores, up 20% YoY.
• EBITDA ₹32 crores; EBITDA margin 4.54%.
• Net profit ₹3 crores; PAT margin 0.44%.
• Order book ₹2,473 crores as of June 2026; bid pipeline ₹9,777 crores.
• Hyundai contract win ~USD 52 million announced post-quarter.

Segment Update

• Treatment Solutions revenue ₹210 crores; EBIT loss ₹17 crores.
• Industrial Products revenue ₹105 crores; EBIT ₹13 crores; EBIT margin 11.89%.
• Lifecycle Services revenue ₹72 crores; EBIT ₹7 crores; EBIT margin 9.92%.
• Specialty Chemicals revenue ₹230 crores; EBIT ₹22 crores.
• Consumer Products revenue ₹112 crores; EBIT loss ~₹0.34 crores.

Projects and Capex

• Roha plant commissioned; capacity expansion targeted 5x total.
• Phase I Roha expansion doubles capacity; Phase II to ~5x total.
• Ankleshwar pharma resins: 6x capacity expansion; FDA-approved facility.
• Goa membranes: full UF/NF/MBR range; MANN+HUMMEL tie-up; second plant coming.
• Lifecycle Services: 200+ O&M contracts; 30,000+ customers served; BOOT/rental focus.

Outlook and Guidance

• Profitability to improve as Roha stabilizes; overseas volumes expected.
• Specialty Chemicals capacity expansion to raise revenue by at least 50% over 2 years.
• Consumer segment to break even in this financial year.
• Roha capacity utilization to contribute to overseas markets; North America WQA certification supports growth.
• Aspire to take roughly 10% of global resin volume via Roha/Ankleshwar.

Q&A Highlights

• Portugal margins: not disclosed; overall margins similar or better than India.
• Roha expansion: Phase I 2x; Phase II to 5x total; target ~10% of global resin volume.
• Pharma resins: 6x capacity; process in next 12 months; capex manageable.
• WQA certification: quantification not provided; Roha overseas volume expected.
• UP legacy: not fully closed; funds-flow constraints; progress by year-end.
• Consumer break-even: target this financial year.

Meeting Details

• Date: August 10, 2026
• Time: not disclosed
• Type: Group meet with investors and analysts
• Mode: not disclosed
• Event: Earnings Conference Call for Q1 FY 2026-27
• Organiser: Ion Exchange India Limited

Participants

• Key company participant: Company Secretary & Compliance Officer

Purpose

• Discuss operational and financial performance for Q1 FY 2026-27

Additional Notes

• Recording available: audio recording of earnings call on company website

Business Overview

• Core business: water treatment and environmental management solutions.
• Segments span Industrial Products, Lifecycle Services, Specialty Chemicals, and Consumer Products.
• Strategic focus on Zero Liquid Discharge and PFAS treatment.

Operational Highlights

• 2X capacity expansion in Industrial Resins to boost global share.
• 5X capacity expansion in Pharma Resins at Ankleshwar.
• 3X growth in membrane platform (RO/UF/NF/MBR) at Goa.
• India's first Non-Solvent Resin facility; integrated Spent Acid Recovery.
• Indigenous UF hollow fiber membrane manufacturing commissioned.
• ZeroB Home Water Solutions expanding alkaline and hydrogen portfolios.
• Lifecycle Services: 200+ O&M contracts; 10% CAGR.
• M2S preventive maintenance software; remote monitoring.
• BOOT/BOOT/WaaS spares and consumables; rentals.
• 30% international revenue share; 50+ countries served.

Financial Performance

• International revenue share: 30%.
• Global installations exceed 200,000.
• 14 global facilities and assembly centres.
• Over 200 O&M contracts; 30,000+ customers.

Capital Structure & Liquidity

• No changes in debt, equity, or liquidity disclosed in this update.

Strategic Priorities & Outlook

• Expand Industrial Resins and Pharma Resins capacity to meet demand.
• Grow membrane platform with 3X capacity across RO/UF/NF/MBR.
• Advance Make in India; indigenous manufacturing and FDA/WHO/ISO compliance.
• Circular manufacturing via spent acid recovery; ZLD and green infrastructure.
• Digital solutions: M2S and remote monitoring; predictive maintenance.
• ZeroB brand expansion; omnichannel reach and service-operations digitization.
• PFAS and UPW opportunities targeted in portfolio expansion.
• Leverage 50+ countries and 200k installations for growth.

Governance & Leadership

• Company Secretary & Compliance Officer: Nikisha Solanki.
• Revised investor presentation released August 2026.

Event

• Earnings presentation for Q1 FY27 with standalone and consolidated highlights released to investors.

Standalone Highlights

• Standalone Q1 FY27: Operating Income 6,356 Mn, EBITDA 307 Mn, PAT 114 Mn.

Consolidated Highlights

• Consolidated Q1 FY27: Revenue 7,005 Mn, EBITDA 318 Mn, PAT 31 Mn, EPS 0.347.

Backlog & Pipeline

• Total order book ~ INR 24,730 Mn; Bid Pipeline ~ INR 97,770 Mn.

Segment Highlights

• Treatment Solutions revenue grew 16%; GCC dispatches resumed.
• Industrial Products revenue grew 19%; EBIT improved to 12.99%.
• Lifecycle Services revenue grew 25%; EBIT rose to 10.56%.
• Specialty Chemicals revenue grew 27%; EBIT impacted by Roha capex.
• Consumer Products revenue grew 33%; EBIT remained negative at -0.36%.